Evidence map›Paper›PMID 39088875›Full record

ArticlePathology, research and practice2024

Multimodal assessment of high-risk human papillomavirus in sinonasal squamous cell carcinoma.

Anna Zhou, Anish Sharma, Damaris Kuhnell, Benjamin H Hinrichs, Ady Kendler, Jiang Wang, Kelsey Dillehey-McKillip, Alice L Tang, Vinita Takiar, Trisha M Wise-Draper and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathology, research and practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anna ZhouUniversity of Cincinnati College of Medicine, Cincinnati, OH, United States.
Anish SharmaUniversity of Cincinnati College of Medicine, Cincinnati, OH, United States.
Damaris KuhnellDepartment of Environmental & Public Health Sciences, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Benjamin H HinrichsDepartment of Pathology & Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Ady KendlerDepartment of Pathology & Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Jiang WangDepartment of Pathology & Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, United States; University of Cincinnati Cancer Center, Cincinnati, OH, United States.
Kelsey Dillehey-McKillipDepartment of Pathology & Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, United States; University of Cincinnati Cancer Center, Cincinnati, OH, United States.
Alice L TangUniversity of Cincinnati Cancer Center, Cincinnati, OH, United States; Department of Otolaryngology, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Vinita TakiarUniversity of Cincinnati Cancer Center, Cincinnati, OH, United States; Department of Radiation Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, United States; Staff Scientist, Cincinnati VA Medical Center, Cincinnati, OH, United States.
Trisha M Wise-DraperUniversity of Cincinnati Cancer Center, Cincinnati, OH, United States; Division of Hematology & Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Scott M LangevinDivision of Hematology & Oncology, Department of Medicine, University of Vermont Larner College of Medicine, Burlington, VT, United States; University of Vermont Cancer Center, Burlington, VT, United States. Electronic address: scott.langevin@med.uvm.edu.

Funding

BLRD VA IK2 BX004360
6 · The paper itself

Abstract

High-risk human papillomavirus (hrHPV) is an emerging risk factor for sinonasal squamous cell carcinoma (SNSCC). The goal of this study was to assess the prevalence of hrHPV and subtype distribution in SNSCC and correlation with patient and clinical characteristics. This retrospective cohort study included 43 cases diagnosed with incident primary SNSCC at the University of Cincinnati Medical Center from 2010 to 2015. The prevalence of hrHPV was interrogated using a multi-assay approach that included p16 immunohistochemistry (IHC), RNA in-situ hybridization (ISH), and hrHPV DNA sequencing. The association of hrHPV with 5-year overall survival (OS) and 2-year disease-free survival (DFS) was assessed. Fourteen cases (32.6 %) were classified as hrHPV positive, based on the a priori definition of having either a positive RNAScope™ ISH test or hrHPV DNA and p16-positive IHC; 9 cases (20.9 %) were positive for all three tests. All cases that arose from an inverted sinonasal papilloma (ex-ISP) were negative for hrHPV. HPV16 was the most common subtype among hrHPV positive cases (58.8 %), followed by HPV18 (17.6 %). No significant association was observed between hrHPV and OS or DFS after adjusting for potential confounding. hrHPV is prevalent in a sizable fraction of SNSCC. Additional studies are needed to better elucidate the relationship with patient survival outcomes and determine the optimal testing modality for prognostication.

Indexed as

Human Papillomavirus VirusesPapillomavirus InfectionsParanasal Sinus NeoplasmsSquamous Cell Carcinoma of Head and NeckHumansImmunohistochemistryRetrospective StudiesHPVNasal cancerP16RNA ISHSinus cancerSurvivalTypeSeq

Identifiers

PMID39088875
PMCPMC12512022

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.